CJC-1295 or Tesamorelin: what each shows

CJC-1295 and tesamorelin are the two most-cited GHRH (growth hormone-releasing hormone) analogs in the research literature on GH secretion, but the volume and type of published evidence differs between them. Tesamorelin has a broader, more established base of controlled human trials; CJC-1295 has more mechanism and pharmacokinetic studies, and much of what gets cited as "CJC-1295 research" actually describes the DAC variant, not the one sold without DAC.

What the two compounds share

Both are synthetic GHRH analogs that act on the GHRH receptor expressed on somatotroph cells in the pituitary. Activating that receptor triggers pulsatile release of growth hormone (GH), which in turn drives hepatic IGF-1 production. That is the axis both compounds are studied against: GHRH → pituitary receptor → GH pulse → circulating IGF-1.

The difference between them is not the receptor — it is the same one — but the structure of the molecule, how long it stays active in circulation, and how closely it reproduces the natural pulsatile pattern of endogenous GHRH. Those three variables are what the literature actually measures when comparing one analog against the other.

CJC-1295: what the literature shows, and which version

The name CJC-1295 actually refers to two distinct molecules that get conflated in search results: the DAC version (Drug Affinity Complex, a group that binds serum albumin and extends half-life to several days) and the no-DAC version, which is what the CJC-1295 catalogue page lists, and which structurally corresponds to the first 29 amino acids of GHRH modified to resist enzymatic degradation (also referred to in the literature as Mod GRF 1-29).

Most of the formal studies on "CJC-1295" — the ones reporting sustained elevations in GH and IGF-1 for days after a single administration in research models — describe the DAC version, whose extended half-life is exactly what produces that prolonged effect. The no-DAC version has a half-life measured in minutes, and in experimental protocols it behaves closer to native GHRH: it produces a GH pulse that follows the physiological pattern rather than a flat, sustained elevation.

That distinction is the one most often lost when someone searches for "CJC-1295 research" and finds results that actually describe the DAC molecule. Before comparing data across studies, it is worth confirming which of the two variants a given protocol used, because the pharmacokinetic profile each reports is not interchangeable.

Tesamorelin: what the literature shows

Tesamorelin is a 44-amino-acid GHRH analog, stabilized with a trans-3-hexenoic group at the N-terminus, which gives it a longer half-life than native GHRH without relying on an albumin-binding system like DAC. It is the molecule in this family with the largest volume of published human clinical trials: there is a substantial base of controlled studies that evaluated its effect on the GH/IGF-1 axis and, in particular, on body composition, with a focus on visceral fat reduction.

That volume of clinical-phase trials — larger than what is available for CJC-1295 without DAC — is what usually tips the comparison when someone is looking for the compound with the deepest published record: not because the mechanism differs, but because there are more peer-reviewed studies documenting its behavior in human populations and its pharmacokinetic profile over time.

The differences that matter when reading the studies

Three variables account for most of the difference between what the literature reports on one compound versus the other:

• Half-life: CJC-1295 without DAC has a half-life of minutes; tesamorelin, hours; CJC-1295 with DAC, days. Comparing results without accounting for this leads to wrong conclusions about how long an effect lasts.
• Volume of human studies: tesamorelin accounts for most of the controlled clinical trials in this group of analogs. CJC-1295 without DAC has fewer publications specific to that particular variant.
• What each protocol measures: some studies report serum GH and IGF-1 levels as the primary endpoint; others report changes in body composition over weeks. These are not the same type of data and are not always comparable to each other.

Neither molecule replaces the other in an experimental design. They answer different questions depending on whether the goal is to study an acute GH pulse or a sustained effect on IGF-1 and body composition.

Documentation for each batch

Every compound that leaves our supplier goes through analysis by an external laboratory, Janoshik Analytical. The lowest purity result we have published so far read 99.669% by HPLC; that is the floor we show, not the best result we have had. You can request the certificate of analysis for a specific batch before quoting, to confirm what material it is and under what method it was measured. Details on how to read a certificate of analysis are on the quality page.

How research material gets quoted

PeptoClinic does not sell at a published price or through a shopping cart: it is a technical supply consultancy for research peptides. A researcher describes what they need — compound, quantity, purity specification — and the technical team responds with a written quote, normally within one business day, that includes batch documentation and the shipping route. The full catalogue lists the 19 available compounds, and logistics into Argentina are described on the shipping page.

For laboratory research use only

All material described in this post is supplied strictly for in vitro and laboratory research (Research Use Only). It is not a drug, not a supplement, and is not approved for human or veterinary consumption, diagnosis, or treatment. Nothing in this post constitutes a recommendation for use, dosing, or administration: it describes what published scientific literature reports on each compound, not a protocol to apply.